Pfizer PFE Biopharma — Expected restructuring cost

Similar metrics at other companies

MCOMoodys Analytics — Restructuring and related cost, expected cost

$240M+54.8%

MCOMoodys Investors Service — Restructuring and related cost, expected cost

$110M+15.8%

AONHuman Capital — Expected cost

$70M+16.7%

AONRisk Capital — Expected cost

$290M+31.8%

ERIIEmerging Technologies — Expected restructuring cost

$5.5M—

MATVFAM — Restructuring expected cost

$1.5M+50.0%

FAQ

What is Pfizer's biopharma — expected restructuring cost?

Pfizer (PFE) reported biopharma — expected restructuring cost of $3.7B in Q1 2026.

How has Pfizer's biopharma — expected restructuring cost changed year-over-year?

Pfizer's biopharma — expected restructuring cost increased by 54.2% year-over-year, from $2.4B to $3.7B.

What does biopharma — expected restructuring cost mean?

Represents the estimated future financial obligations associated with planned organizational changes, such as facility closures or workforce reductions within the biopharmaceutical business unit. This metric helps investors gauge the potential impact of future efficiency initiatives on the segment's bottom line.